GLOW & KLOW Peptide Blends: Protocols for Anti-Aging & Skin Rejuvenation

GLOW and KLOW are single-vial peptide cocktails injected under the skin to rebuild collagen, firmness, and texture — the structural layer topical skincare can't reach. GLOW is the three-peptide base (GHK-Cu, BPC-157, full-length TB-4). KLOW adds a fourth, KPV, for skin where inflammation interferes with the rebuilding work — rosacea, post-procedure redness, reactive baselines.

The choice tracks baseline. Calm skin → GLOW. Reactive, post-procedure, or rosacea-pattern → KLOW. Both reconstitute the same way and run on the same dosing schedule, so switching mid-cycle is just a vial swap.

The schedule is daily for weeks 1–4, five times a week for weeks 5–8, then two or three times a week for ongoing maintenance. Texture and tone shift around weeks 2–4, fine lines soften by 4–8, firmer structure and scar remodeling land by 8–12.

Jump to protocol →

GLOW vs. KLOW: Which one is right for you and your skin?

GLOW — best for: aging skin, fine lines, firmness loss, scar improvement, hair growth support, general skin quality.

KLOW — best for: reactive or redness-prone skin, active rosacea or inflammatory acne, post-procedure recovery (laser, microneedling), chronic low-grade facial inflammation.

Not sure? GLOW is the default starting point, with KLOW the switch when inflammation limits results. The two also alternate by skin condition — some practitioners run KLOW during active flares and GLOW during stable periods.

Composition

GLOW is 70 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-4 10 mg. KLOW is 80 mg total: the same three plus KPV 10 mg. GHK-Cu carries 71% of vial mass because collagen synthesis is the continuous daily demand. BPC-157 and TB-4 (and KPV in KLOW) work at lower doses because their effective concentrations are lower — not because they matter less.

GLOW Peptide Blend

KLOW Peptide Blend

The 50/10/10 ratio is designed for cosmetic applications, not injury recovery. For injury use, the cocktail-tied dose math doesn't work — see GLOW/KLOW for Injuries for why and what to use instead.

How to Dose GLOW & KLOW Peptide Blends: Selecting an Anchor Compound

The protocol anchors on 2 mg GHK-Cu per injection. Two reconstitution paths land on the same anchor depending on vial size:

• Standard vial — 2.5 mL BAC water; draw 0.1 mL (10 units on a U-100 insulin syringe) per dose
• Larger vial (5 mL+) — 5 mL BAC water; draw 0.2 mL (20 units) per dose. Cleaner syringe-mark reading and reduced concentration-dependent sting; the trade-off is injecting twice the volume per dose

Either path delivers 2 mg GHK-Cu plus 400 mcg of each support peptide; KLOW adds 400 mcg KPV. Each vial provides 25 doses at either reconstitution.

The 25 comes from the GHK-Cu, not the vial's total mass. Each dose anchors to the 50 mg of GHK-Cu — 50 ÷ 2 = 25 — so it is not 70 mg ÷ 2 mg = 35. KLOW's extra 10 mg of KPV rides along on every shot without changing the draw volume or how long a vial lasts.

For non-standard anchor doses or per-anchor draw volumes, use the KLOW Calculator or GLOW Calculator. General bacteriostatic water and syringe handling lives in the Reconstitution Guide.

How GLOW & KLOW Peptide Blends Work

Skin aging is several systems failing at once: collagen genes firing less, the capillary supply thinning, repair cells losing coordination, and inflammatory tone interfering with rebuilding. Each compound in GLOW and KLOW addresses one of these. Run any one alone and the part the missing compound was meant to handle becomes the rate-limiter for the whole protocol.

GHK-Cu

A copper-binding tripeptide mapped across more than 4,000 genes in gene-expression work: collagen synthesis, antioxidant defense, and wound-healing programs trend up; inflammation and tissue-breakdown programs trend down¹. Circulating levels decline with age: roughly 200 ng/mL at age 20, dropping to 80 ng/mL by age 60¹.

GHK-Cu both clears damaged tissue and lays down replacement collagen — most collagen interventions only do the second.

BPC-157

A 15-amino-acid fragment from gastric juice that stabilizes tissue barriers and builds the capillary supply active regeneration depends on².

BPC-157 builds the capillary supply collagen synthesis depends on². Without blood flow to the dermis, GHK-Cu has the signal but the substrate doesn't reach the work.

TB-4

Full-length thymosin beta-4 (43 amino acids) regulates how repair cells move into and organize inside tissue³.

GLOW and KLOW use full-length TB-4 (43 amino acids). TB-500 is the 17–23 fragment — a different molecule, sold separately, used at higher per-dose levels for acute injury repair. Two practical notes: product labels blur the two routinely⁷, so vial identity matters; and at the cocktail's 400 mcg per dose, TB-4 is doing background tissue-organization work, not injury-grade migration signaling. For injury use, the dose math doesn't add up — see GLOW/KLOW for Injuries for why and what to use instead.

KPV

A three-amino-acid fragment of alpha-MSH (a natural anti-inflammatory hormone)⁴. KPV prevents inflammatory genes from activating in the first place — a more targeted approach than NSAIDs, which block inflammation after it's already started. Normal immune signaling needed for healing stays intact⁴.

KPV's strongest preclinical evidence is for oral delivery to gut tissue, where inflamed intestinal cells actively absorb it via the PepT1 transporter (upregulated during inflammation)⁵. Subcutaneous delivery, as in KLOW, bypasses this targeted pathway and distributes KPV systemically.

Systemic anti-inflammatory effects at injectable doses remain less characterized than gut-directed oral KPV. The dermatological profile is supported by mechanism and clinical practice, but controlled human trials for subcutaneous KPV in KLOW-style blends have not been published.

Three-Phase GLOW Protocol / KLOW Protocol for Skincare

Both GLOW and KLOW use identical scheduling. The per-injection volume is 0.1 mL (10 units on a U-100 insulin syringe) at 2.5 mL reconstitution, or 0.2 mL (20 units) at 5 mL for larger vials — same delivered dose either way. Phases adjust frequency, not the mixture. Use the KLOW Calculator or GLOW Calculator to solve any custom anchor dose, vial size, or draw volume.

*KPV only in KLOW formulation

Phase 1: Activation (Weeks 1-4)

Dose: 0.1 mL (10 units) subcutaneous, daily

GHK-Cu activates collagen production while its copper component enables proper structural cross-linking¹. BPC-157 builds the network of small blood vessels needed to feed active tissue². TB-4 mobilizes and organizes repair cells³. In KLOW, KPV simultaneously suppresses inflammatory interference⁴.

Expected: Skin hydration improves, tone evens, texture softens, redness decreases (particularly with KLOW).

Phase 2: Remodeling (Weeks 5-8)

Dose: 0.1 mL (10 units) subcutaneous, 5×/week

Same per-injection amounts. All compounds at peak coordinated activity.

GHK-Cu drives maximum collagen production — structural proteins, elastin for bounce-back, and the water-binding molecules that keep skin hydrated from within¹. BPC-157 maintains blood flow to active tissue². TB-4 coordinates efficient cell organization³. Small human dermatology studies report meaningful increases in collagen synthesis and reductions in wrinkle depth over 8-12 weeks¹.

Expected: Fine lines soften, elasticity improves, visible glow returns, skin thickness increases.

Phase 3: Maintenance (Weeks 9+)

Dose: 0.1 mL (10 units) subcutaneous, 2-3x weekly

Pulsed administration keeps the repair signal present without turning the protocol into constant stimulation:

• Signal sensitivity — pulsed dosing is the conservative way to avoid blunting the response over time.
• Integration time — newly synthesized collagen needs 48-72 hours between pulses to organize and cross-link.
• Maintenance fit — long-running protocols usually work better as a cadence than as daily pressure forever.

Duration: Ongoing, or quarterly 4-week intensive cycles (return to daily dosing every 3-4 months).

Timeline: What to Expect

Conditional Stacking

GLOW alone handles standard skin quality. KLOW handles reactive or post-procedure baselines. Advanced stacks are not about adding everything; they are about finding the bottleneck that still limits remodeling.

• NAD+ — The main advanced layer, not just a rescue add-on. GHK-Cu-driven remodeling costs energy: repair cells need redox capacity, DNA repair, and enough cellular fuel to keep building. The NAD+ layer fits where the goal is maximum skin remodeling, where GLP-1 use or caloric deficit is present, where fatigue is part of the picture, or where progress stalls after a clean first month.
• Selank — For reactive skin that tracks nervous-system load: stress flares, anxiety-linked flushing, post-meal surges, poor sleep, cortisol pressure, or mast-cell-ish reactivity. It belongs with advanced KLOW, not ordinary calm-skin GLOW.
• Topical GHK-Cu or AHK-Cu + minoxidil — For hair shedding during GLP-1 use, rapid weight loss, or aggressive dieting. The driver comes first: protein, calories, ferritin/iron, zinc, vitamin D, thyroid status, hydration, and training stress. GLOW supports the broader tissue field; hair needs local scalp exposure.
• MT-I / afamelanotide, not MT-II — For pigment and photoprotection when the user also wants smooth, resilient skin. MT-I builds eumelanin with a cleaner receptor profile; GLOW or KLOW maintains the skin-quality layer underneath.
• SS-31 short course — Only for advanced post-procedure recovery: aggressive laser, microneedling, peels, slow rebound, high oxidative load, or clear mitochondrial fatigue. NAD+ is the floor; SS-31 is the short mitochondrial-membrane layer when the procedure stress justifies it.
• Sermorelin / ipamorelin / DSIP — Conditional night-window tools. The narrow case is poor sleep architecture, weak recovery, an older GH-pulse phenotype, or under-recovered training clearly limiting skin remodeling. They are not generic skincare add-ons.

Each layer has dose ranges, phasing, and monitoring. Tell FoxAI your situation and it builds the right stack →

Administration — A Guide

• Route: Subcutaneous (abdomen or thigh)
• Timing: Consistent daily timing; evening preferred (collagen synthesis peaks during deep sleep)
• Sites: Rotate to prevent irritation
• Storage: Refrigerate 2–8°C after reconstitution, stable 30 days, protect from light

The GHK-Cu Sting

A 30–60 second sting after injection is normal — the copper-peptide complex is doing it, not contamination or technique error. The blue color is normal too. Practical mitigations:

• Warm the vial about 10 minutes before drawing
• Inject slowly (a 5-second push)
• 5 mL reconstitution (the standard for larger vials) halves the concentration and reduces concentration-dependent burn — the trade-off is injecting 0.2 mL / 20 units instead of 0.1 mL / 10 units per dose
• Inject deeper subQ rather than intradermal — the upper dermis has more mast cells and reacts more visibly
• Don't co-inject with NAD+. NAD+ is acidic (pH 3-4) and will destabilize the peptide solution. Schedule at least 30 minutes apart, or different days.

A colorless reconstituted solution is more suspicious than a blue one — it can indicate missing or under-dosed GHK-Cu.

Supply Planning

Each vial provides 25 doses regardless of reconstitution choice (2.5 mL ÷ 0.1 mL = 5 mL ÷ 0.2 mL = 25):

• Weeks 1-4 (daily): 28 doses
• Weeks 5-8 (5x weekly): 20 doses
• Weeks 9-12 (2-3x weekly): 8-12 doses
• Total: 56-60 doses, usually 3 vials for a 12-week protocol

Supporting Factors: Diet, Vitamins, Hydration, Sleep

Optional adjuncts:

• Red light therapy (630-670 nm): 10-20 min daily
• Microneedling: Every 3-4 weeks during Phase 2

When Progress Stalls during a GLOW / KLOW Protocol

Each stall pattern has a different fix, and the signal is what distinguishes them — not the impulse to push harder.

Plateau at week 4–6 with clean execution

• Likely meaning: The architectural work has hit the protocol's energy envelope. GHK-Cu remodeling and inflammatory resolution both draw on NAD+ for energy, redox control, and DNA repair.
• Move: NAD+ or tighter recovery support, not an escalated GLOW/KLOW dose.

Reactive skin emerges on GLOW

• Likely meaning: Inflammatory tone is interfering. Collagen and vascular signals are landing on tissue that is fighting the signal.
• Move: The switch to KLOW, not pushing through on GLOW.

Persistent inflammation past week 6 on KLOW

• Likely meaning: The driver may be mast-cell-mediated, systemic, or upstream of NF-κB rather than dermal-local.
• Move: The next layer is mast-cell-targeted work, gut-axis evaluation, or clinical workup, not a dose-escalated KLOW.

Results are weak across the board

• Likely meaning: Substrate shortage. Collagen synthesis needs raw material.
• Move: The checklist is protein floor, vitamin C, copper-zinc balance, reconstitution/storage technique, sleep, and calories — ahead of adding more compounds.

Skin calms but gut symptoms remain

• Likely meaning: Subcutaneous KLOW does not reach the gut surface. KPV's strongest gut work is oral, where inflamed intestinal cells actively absorb it through PepT1.
• Move: It reads as a different route and a different problem: oral KPV or a gut-immune protocol, not more KLOW.

Phenotype Considerations

A few user profiles change the default protocol shape:

• Perimenopausal female. Estrogen-driven collagen decline accelerates during perimenopause, and most users land here with substrate already more depleted at baseline. The activation phase runs longer before visible results — 12-week protocols rather than 8 are the reasonable shape.
• Recent surgery. The standard convention defers the protocol at least two weeks after major surgery. Excessive angiogenesis during early surgical healing can complicate scar formation. After two weeks the scar-remodeling axis is when the protocol is most useful.
• Post-procedure (laser, microneedling, peels). KLOW can begin roughly 48–72 hours after minor procedures, once the initial inflammatory cascade has peaked. New compounds stay out through the acute first week — the procedure's own repair signal runs before anything layers on top.
• MCAS or mast-cell-pattern reactivity. KPV addresses NF-κB-mediated skin inflammation but not mast-cell activation. If reactive-skin pattern persists past six weeks on KLOW, mast-cell-targeted work is the right next layer — not KLOW dose escalation.

Safety & Contraindications

Contraindications:

• Active malignancy or cancer history <5 years (BPC-157, TB-4, and GHK-Cu promote new blood vessel formation)
• Wilson's disease or copper metabolism disorders (GHK-Cu)
• Pregnancy or breastfeeding
• Major surgery within the past 2 weeks
• Known allergy to any component

Side effects (uncommon):

• Mild injection site reactions (redness, slight swelling)
• Transient warmth, flushing, or mild fatigue
• Persistent hives, swelling, throat tightness, or breathing changes are not a normal peptide flush

Cycling recommendation: Blend-level long-term human data do not exist, so indefinite daily use is not the default — see the Three-Phase Protocol section above for the canonical schedule.

What Evidence Exists for Each Peptide in the GLOW & KLOW Peptide Blends

GHK-Cu — Split-face human dermatology trials on facial wrinkle depth and skin density (n typically <50 per arm); microarray gene-expression mapping (>4,000 genes); fifty-plus years of cosmetic and wound-healing literature. No multi-center RCT.

BPC-157 — 100+ preclinical studies across rodent injury, GI, and tendon models; small early human trials (2024–2025) on tendon and gut indications; broad cytoprotective profile across tissues. No published Phase 3.

TB-4 — Preclinical wound-healing data (cardiac, dermal, neural); Phase 2/3 ophthalmic trials in corneal healing (RGN-259); cosmetic dosing extrapolated from injury models — no standardized cosmetic-endpoint trial.

KPV — Mechanistic data on NF-κB pathway suppression; small clinical trials in IBD (oral route) and atopic dermatitis (topical/oral); subcutaneous-route human data for systemic anti-inflammatory effects has not been published.

No controlled trial has evaluated GLOW or KLOW as a blended formulation. Synergy is inferred from individual-component mechanisms, not demonstrated in combination studies.

FAQ

Related Topics

• GHK-Cu for Skin — GHK-Cu mechanism deep-dive
• KLOW Dosing Calculator — Skincare vs injury anchor math, plus why TB-4 is underdosed at the injury anchor
• BPC-157 Guide — BPC-157 standalone use
• Wolverine Stack — BPC-157 + TB-500 for injury
• NAD+ Guide — Cellular energy for recovery
• Where to Inject Peptides — Injection guide for GLOW/KLOW and individual compounds
• Peptide Reconstitution Calculator — Technique for all peptide vials
• TB-500 Guide — Thymosin Beta-4 fragment used in injury protocols (distinct from TB-4 in GLOW/KLOW)

References

¹ GHK-Cu gene modulation — COL1A1/COL3A1 collagen gene activation, lysyl oxidase cross-linking, bidirectional MMP regulation, SOD/catalase antioxidant expression, 4,000+ gene modulation via microarray: Pickart L, Margolina A. Int J Mol Sci 2018. DOI: 10.3390/ijms19071987; Pickart L. J Biomater Sci Polym Ed 2008. PubMed: 18644225

² BPC-157 angiogenic signaling and pharmacokinetics — VEGF expression, tight junction upregulation, capillary sprouting, microvascular network formation; independent rodent and dog IV PK characterization; preclinical and clinical evidence map: Sikiric P et al. Curr Pharm Des 2018. PubMed: 29737246; He L et al. Front Pharmacol 2022. PMC9794587; Vasireddi N et al. HSS J 2025. PubMed: 40756949

³ Thymosin beta-4 tissue repair, structure, and pharmacokinetics — G-actin sequestration for cell mobility, TGF-beta anti-scarring regulation, M2 macrophage polarization, endothelial anti-inflammatory effects; α-helix actin-binding structural basis; first-in-human IV PK: Goldstein AL et al. Trends Mol Med 2005. PubMed: 16099219; Xue B et al. Proc Natl Acad Sci 2014. PMC4217450; Wang P et al. J Cell Mol Med 2021. PMC8419156

⁴ KPV anti-inflammatory mechanism — NF-κB inhibition, cytokine suppression, M1→M2 immune cell shift, mast cell stabilization; non-melanocortin-receptor / non-cAMP mechanism distinct from α-MSH parent: Luger TA, Brzoska T. Ann Rheum Dis 2007. PubMed: 17921186; Getting SJ, Schiöth HB, Perretti M. J Pharmacol Exp Ther 2003. PubMed: 12750433

⁵ KPV oral delivery via PepT1 — PepT1 transporter uptake in inflamed intestinal tissue, murine IBD models, intracellular NF-κB and MAP kinase suppression at nanomolar concentrations, PepT1-knockout loss-of-function proof: Kannengiesser K et al. J Crohns Colitis 2008. PubMed: 21172189; Dalmasso G et al. Gastroenterology 2008. PMC2431115; Viennois E et al. Cell Mol Gastroenterol Hepatol 2016. PMC4957955

⁶ TB-4 wound healing — dermal repair acceleration, full-length peptide in wound models: Malinda KM et al. J Invest Dermatol 1999. PubMed: 10469299

⁷ TB-4 / TB-500 product mislabeling — documented bidirectional mislabeling between full-length TB-4 (43 amino acids) and the TB-500 fragment (17–23, 7 amino acids) in marketed peptide products: Esposito M et al. Drug Test Anal 2012. PubMed: 22962027